HOME > TOP STORIES

TOP STORIES

REGULATORY In Fight against AMR, Japan Set to Forge Prefectural Networks to Push Proper Antibiotic Use

September 5, 2019
BUSINESS Roche/Chugai’s Rozlytrek, AstraZeneca COPD Combos and More Hit Shelves

September 5, 2019
BUSINESS Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing

September 4, 2019
BUSINESS Astellas Grabs Global Rights to RIKEN’s aAVC Technology in Oncology

September 3, 2019
BUSINESS Astellas Revving Up Digital Transformation Drive, Expands Scope of Data to Derive Values

September 2, 2019
TRENDS Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up

August 30, 2019
REGULATORY MHLW Panel Puts a Hold on Possible World’s 1st OK for Ono’s Cancer Cachexia Drug

August 30, 2019
ORGANIZATION Japan Doctors’ Group Raps Payer Proposal to Scrap Coverage for Pollen Allergy Drugs

August 29, 2019
REGULATORY Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4

August 28, 2019
REGULATORY Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen

August 28, 2019
REGULATORY Tagrisso to Face 15% Price Cut in November Because It Sold Too Well

August 27, 2019
ORGANIZATION Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen

August 26, 2019
REGULATORY Japan to Set Up Dedicated Team to Expedite Review of Sakigake-Designated Cell/Gene Therapies

August 23, 2019
REGULATORY Tecentriq Wins Japan Nod for SCLC as 1st Checkpoint Drug for This Use

August 23, 2019
BUSINESS Price Revision Rates in October Re-Pricing Vary in Crowded DPP-4 Class: Survey

August 22, 2019
BUSINESS Frontloaded Price Cuts before Regular April Revision Hurts, Say Drug Makers

August 21, 2019
REGULATORY No PMP for Tecentriq, but Prices Rise for All 5 Checkpoint Drugs in Tax Hike Re-Pricing

August 21, 2019
BUSINESS Tax Hike Re-Pricing Slams Small Pharma and Gx Players, Impact Milder for Big Firms: Survey

August 20, 2019
REGULATORY Kymriah, All Checkpoint Drugs but Tecentriq to Get Price Maintenance Premium in October Re-Pricing

August 20, 2019
BUSINESS Sumitomo Dainippon Flip-Plops on Sales Force Cutback as It Ramps Up Diabetes Push

August 19, 2019

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…